RxDoctor Payments Data

Brian McNichols

Interventional Cardiology · Rochester, NYNPI 1922495852

Payments from drug & device makers

$3,438in general payments, 2019–2025

Across 101 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Inari Medical, Inc.$686
  • Novartis$322
  • Stryker$257
  • Boston Scientific$242
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$161
  • plus $230 from 7 others

What the payments were for

  • Travel & lodging$57917%
  • Food & beverage$2,57975%
  • Education$2808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,438 in reported general payments places this provider in the 20th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$194,775
Medicare patients
747
Services billed
2,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$161,686
EntrestoSacubitril/Valsartan79$60,182
BrilintaTicagrelor108$53,814
JardianceEmpagliflozin18$17,220
XareltoRivaroxaban16$14,274
Repatha SureclickEvolocumab18$13,639
Ranolazine ErRanolazine20$3,360
Metoprolol Succinate159$2,337
Rosuvastatin Calcium112$1,925
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,641
Atorvastatin Calcium118$1,260
Prasugrel Hcl20$1,251
Amiodarone Hcl22$1,055
Losartan Potassium72$850
ClopidogrelClopidogrel Bisulfate82$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$161,686158 claims
NovartisEntresto$322$60,18279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →